Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Return on Equity (2020 - 2025)

Vivos Therapeutics' Return on Equity history spans 6 years, with the latest figure at 40.75% for Q4 2025.

  • Quarterly results put Return on Equity at 40.75% for Q4 2025, down 3932.0% from a year ago — trailing twelve months through Dec 2025 was 40.75% (down 3932.0% YoY), and the annual figure for FY2025 was 6.57%, down 391.0%.
  • Return on Equity for Q4 2025 was 40.75% at Vivos Therapeutics, down from 4.81% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 7.93% in Q3 2023 to a low of 59.44% in Q4 2023.
  • The 5-year median for Return on Equity is 0.72% (2021), against an average of 7.06%.
  • The sharpest move saw Return on Equity plummeted -5946bps in 2023, then skyrocketed 5802bps in 2024.
  • Year by year, Return on Equity stood at 0.0% in 2021, then skyrocketed by 1962bps to 0.01% in 2022, then tumbled by -440107bps to 59.44% in 2023, then skyrocketed by 98bps to 1.43% in 2024, then tumbled by -2758bps to 40.75% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 40.75%, 4.81%, and 3.19% for Q4 2025, Q3 2025, and Q2 2025 respectively.